NYSE: TFX ยท Medical Instruments & Supplies
Teleflex (TFX) fair value and price range
As of 22 Sep 2026, Faircurve's model values Teleflex (TFX) at $127.50 a share. The stock last closed at $124.80, which puts the model's fair value 2.2% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 21 Sep 2026. Teleflex Incorporated.
What price range does the model give TFX?
The calibrated range for TFX over 63 trading days is $114.06 to $147.89. It sits around the last close, and its width comes from the volatility that TFX's own options imply (37% a year), calibrated weekly against realised prices (n = 2,982 past valuations, refreshed 19 Sep 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $67.53 to $209.65. In 51% of the simulations the fair value came out above the price the model ran on.
How does TFX score on business quality?
Teleflex's overall quality score is 59 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 29 | 1.5%ROIC | -0.3% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 100 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 43 | -34.6%Revenue growth, trailing | 9.1% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 99 | 4.5%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 70 | -10.81xNet debt / EBITDA | 9.32x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 45 | 4.8 ptsEBITDA margin downside volatility, 5y | 3.7 pts |
How does TFX compare with similar companies?
The companies in medical instruments & supplies closest to Teleflex in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| MMSI Merit Medical Systems, Inc. | $85.49 | $87.45 | +2.3% | Fairly valued |
| ATR AptarGroup, Inc. | $123.40 | $123.68 | +0.2% | Fairly valued |
| ICUI ICU Medical, Inc. | $155.22 | $184.60 | +18.9% | Undervalued |
| RGEN Repligen Corporation | $180.71 | $142.83 | -21.0% | Overvalued |
| AVTR Avantor, Inc. | $15.10 | $18.27 | +21.0% | Low model confidence |
| COO The Cooper Companies, Inc. | $54.12 | $57.26 | +5.8% | Fairly valued |
| BAX Baxter International Inc. | $22.93 | $24.40 | +6.4% | Fairly valued |
| SOLV Solventum Corporation | $88.84 | $95.83 | +7.9% | Fairly valued |
All medical instruments & supplies stocks ranked by gap to fair value
When does TFX report earnings, and how has the stock reacted?
Teleflex's next earnings report is scheduled for 5 Nov 2026. Companies can move their dates.
Options prices on 21 Sep 2026 imply a move of about 7.5% in either direction through the nearest expiry, about 24 days out. That is the size the market is pricing, not a direction. TFX's 30 day implied volatility works out to about 10.6% over one month.
How TFX moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 9.6%.
| Report date | Two session move |
|---|---|
| 6 Aug 2026 | -1.3% |
| 7 May 2026 | +8.0% |
| 26 Feb 2026 | +9.1% |
| 6 Nov 2025 | -12.3% |
| 31 Jul 2025 | +1.7% |
| 1 May 2025 | -12.5% |
| 27 Feb 2025 | -25.3% |
| 31 Oct 2024 | -10.2% |
Teleflex at a glance
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices.
- Market value
- $5.5B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Revenue expected, next twelve months
- $2.3B
- Consensus revenue growth, next fiscal year
- +13.8%
- Analysts with estimates
- 6
- Beta to the US market
- 0.73
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Teleflex on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for TFX was $127.25. As of 22 Sep 2026 it is $127.50, a change of +0.2%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Teleflex's valuation
Is Teleflex stock undervalued or overvalued?
Faircurve's model puts TFX's fair value at $127.50 a share against a last close of $124.80, as of 22 Sep 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is TFX's fair value?
$127.50 a share as of 22 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $67.53 to $209.65.
What price range does the model give TFX?
$114.06 to $147.89 over 63 trading days. Ranges built this way held the price 60% of the time across 2,982 past valuations, refreshed 19 Sep 2026.
When does Teleflex report earnings next?
The next report is scheduled for 5 Nov 2026. Companies can move their dates.
How much has TFX moved on past earnings reports?
Across its last 8 reports the median two session move was 9.6%, ignoring direction. The largest was -25.3% around the report of 27 Feb 2025.
How confident is the model in this valuation?
Model confidence for TFX is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.